Relay Therapeutics (RLAY) Leases (2020 - 2025)
Relay Therapeutics (RLAY) has disclosed Leases for 6 consecutive years, with $40.0 million as the latest value for Q4 2025.
- Quarterly Leases fell 22.74% to $40.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.0 million through Dec 2025, down 22.74% year-over-year, with the annual reading at $40.0 million for FY2025, 22.74% down from the prior year.
- Leases for Q4 2025 was $40.0 million at Relay Therapeutics, down from $41.4 million in the prior quarter.
- The five-year high for Leases was $65.2 million in Q3 2022, with the low at $19.8 million in Q2 2022.
- Average Leases over 5 years is $45.5 million, with a median of $51.8 million recorded in 2024.
- The sharpest move saw Leases skyrocketed 207.2% in 2023, then dropped 22.74% in 2025.
- Over 5 years, Leases stood at $20.8 million in 2021, then skyrocketed by 206.8% to $63.8 million in 2022, then dropped by 9.07% to $58.0 million in 2023, then dropped by 10.71% to $51.8 million in 2024, then decreased by 22.74% to $40.0 million in 2025.
- According to Business Quant data, Leases over the past three periods came in at $40.0 million, $41.4 million, and $42.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.